The role of background diet on the effects of eicosapentaenoic acid and docosahexaenoic acid supplementation in healthy pre-menopausal women: a randomized, cross-over, controlled study.
BACKGROUND
The links between dietary fat intake, polyunsaturated fatty acid intake and breast cancer risk remain equivocal, with some studies pointing to improvements in risk upon omega-3 supplementation. However, the background diet is poorly controlled in most studies, potentially confounding this link. Therefore, this study examined the hypothesis that in order to see the benefits of omega-3 fatty acid supplementation, the background diet must be low in fat.


METHODS
Of the 56 healthy, pre-menopausal women randomized to one of two experimental arms, consisting of a two-treatment, randomized, cross-over design, 41 completed the 10 month intervention. The two diet phases (habitual and low-fat) were separated by a washout phase, each lasting 3 menstrual cycles. During each diet phase, women were supplemented with 1.2 g eicosapentaenoic acid + docosahexaenoic acid per day.


RESULTS
Red blood cell fatty acid composition indicated that more eicosapentaenoic acid and docosahexaenoic acid was incorporated in the low-fat diet than the habitual diet, though both diet phases resulted in significant increases in the omega-3 to omega-6 ratio. In the context of omega-3 supplementation in breast cancer risk reduction, we also measured fatty acid incorporation into nipple aspirate fluid. Similar changes to red blood cells were noted in nipple aspirate fluid, with higher incorporation of eicosapentaenoic acid in the low-fat diet phase.


CONCLUSIONS
These data suggest that the total level of dietary fat has some direct impact on fatty acid partitioning in addition to the recognized importance of fatty acid ratios, and supports the hypothesis that dietary fat intake must be considered a confounder in supplementation trials. Additionally, we demonstrate that n3 supplementation both reaches and imparts improvements in lipid content and n3:n6 at the target breast tissue.


BACKGROUND
Trial was been retrospectively registered at clinicaltrials.gov (Reg NCT02816125 ).
Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Megan Arnold
MA
Gomes
Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Xiaoyuan
X
Jia
Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Iris
I
Kolenski
Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Alison M
AM
Duncan
Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, ON, N1G 2W1, Canada. kmecklin@uoguelph.ca.
Kelly A
KA
Meckling
Estrogen; Estrogen metabolites; Nipple aspirate; Omega-3 fatty acids; Urinary biomarkers
Biomed Pharmacother. 2006 Nov;60(9):502-7
17045449
Int J Cancer. 2004 Jul 1;110(4):589-97
15122593
BMJ. 2013 Jun 27;346:f3706
23814120
J Natl Cancer Inst. 1995 Apr 19;87(8):587-92
7752256
Am J Clin Nutr. 1997 Oct;66(4 Suppl):998S-1003S
9322580
Breast Cancer Res. 2015 May 04;17:62
25936773
JAMA. 1999 Mar 10;281(10):914-20
10078488
Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):906-12
15824162
Am J Clin Nutr. 2005 Jun;81(6):1298-306
15941879
Crit Rev Clin Lab Sci. 2004;41(1):41-78
15077723
J Nutr. 2004 Dec;134(12 Suppl):3412S-3420S
15570047
J Natl Cancer Inst. 2005 Oct 5;97(19):1458-65
16204695
Epidemiology. 2006 Jan;17(1):80-8
16357599
Am J Clin Nutr. 2007 Apr;85(4):1090-7
17413110
Psychooncology. 2006 Oct;15(10):873-83
16374894
Cancer Prev Res (Phila). 2011 Dec;4(12):2062-71
22027686
Clin Cancer Res. 2004 Nov 15;10(22):7500-10
15569980
Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9372-7
9256489
Cancer Causes Control. 2011 Apr;22(4):529-40
21286801
Br J Nutr. 2005 Apr;93(4):519-27
15946415
Pediatr Res. 2000 Dec;48(6):835-41
11102555
Annu Rev Nutr. 2000;20:221-48
10940333
J Womens Health (Larchmt). 2003 Mar;12 (2):183-92
12737717
BMC Cancer. 2014 Feb 18;14:105
24548731
Br J Cancer. 1997;76(4):494-501
9275027
Biomark Med. 2007 Aug;1(2):251-60
20477400
Am J Clin Nutr. 2006 Feb;83(2):227-36
16469979
Br J Cancer. 2002 May 6;86(9):1440-3
11986778
J Intern Med. 2001 May;249(5):395-411
11350564
Nutr Cancer. 1981;2(4):232-6
6810319
Epilepsy Behav. 2005 Sep;7(2):253-8
16006194
JAMA. 2006 Feb 8;295(6):629-42
16467232
Int J Womens Health. 2011 Feb 08;3:37-51
21339936
Lipids. 1997 Mar;32(3):293-302
9076666
Breast J. 2001 Nov-Dec;7(6):378-87
11843848
Am J Clin Nutr. 1997 Dec;66(6 Suppl):1557S-1563S
9394715
Can J Biochem Physiol. 1959 Aug;37(8):911-7
13671378
Breast Cancer Res Treat. 1999 Feb;53(3):241-53
10369070
Prostaglandins Leukot Essent Fatty Acids. 2002 Jan;66(1):83-90
12051959
Lipids. 2005 Aug;40(8):807-14
16296399
N Engl J Med. 1996 Feb 8;334(6):356-61
8538706
Anal Biochem. 1976 May 7;72:248-54
942051
Can J Physiol Pharmacol. 2002 Nov;80(11):1095-105
12489929
Int J Cancer. 2001 Jun 1;92(5):767-74
11340585
Nutrition. 1998 Sep;14 (9):722-4
9760600
J Natl Cancer Inst. 1997 Jun 4;89(11):766-75
9182974
Carcinogenesis. 1999 Dec;20(12):2209-18
10590211
J Natl Cancer Inst. 2006 Oct 4;98(19):1406-15
17018787
Clin Cancer Res. 1999 Dec;5(12):3942-7
10632323
Pharmacol Ther. 1999 Sep;83(3):217-44
10576293
Cancer Epidemiol Biomarkers Prev. 2012 Feb;21(2):319-26
22194528